

# Filgotinib for treating moderately to severely active ulcerative colitis

Information for the public

Published: 1 June 2022

[www.nice.org.uk](http://www.nice.org.uk)

Filgotinib (Jyseleca) is available on the NHS as a possible treatment for moderately to severely active ulcerative colitis in adults if:

- you cannot tolerate conventional treatments (aminosalicylates, corticosteroids or thiopurines), biological treatments (adalimumab, golimumab, infliximab, ustekinumab or vedolizumab) or tofacitinib, or
- your condition has not got better or has stopped getting better while on them.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS website](#) may be a good place to find out more.

[Crohn's and Colitis UK](#) (0300 222 5700) can give you advice and support.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4586-3